Comprehensive AI In Pharma Market Forecast 2025-2034: Growth Trends and Strategic Shifts

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

AI In Pharma Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the recent years, the size of the AI in Pharma market has seen an astronomical growth. It is forecasted to expand from $2.92 billion in 2024 to $3.78 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 29.5%. The significant growth during the historical period is due to the enhanced adoption of artificial intelligence in order to economize drug discovery process and the escalating application of AI in radiology.

AI In Pharma Market Size Forecast: What's the Projected Valuation by 2029?
The market size for ai in pharma is projected to experience a significant surge in the upcoming years, reaching a value of $9.29 billion by 2029 with an estimated compound annual growth rate (CAGR) of 25.2%. This positive forecast period growth can be linked to the embracement of cloud-based apps and services by pharmaceutical entities, a rise in healthcare spending, and increasing government backing for AI development. Key trends expected within the forecast period encompass the launch of generative AI in the pharmaceutical sector, the application of AI in pinpointing molecular targets, the incorporation of AI into the drug screening process, advancements in AI utilities for the pharma industry, escalating investments tailored towards creating novel product solutions, and the formation of strategic alliances and cooperation among market players.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ai-in-pharma-global-market-report

What Are the Drivers Transforming the AI In Pharma Market?
The expansion of the AI in pharma market is predicted to be accelerated by increasing government support for AI advancements. The potential of AI technologies to revolutionize the pharmaceutical industry is recognized by governments, leading to the implementation of policies and efforts to encourage their usage. Several nations have formulated national AI strategies that prioritize healthcare and pharmaceutical facets. The purpose of these strategies is to spur the growth and application of AI technology in order to foster scientific progression and address real-world issues. For instance, the Australian government in April 2022 launched a AUD44 million ($29.61 million) funding scheme to bolster AI research within small to medium-sized enterprises (SMEs). The initiative constitutes a wider strategy to enhance the use of AI in Australia's national manufacturing priority sectors, including the pharmaceutical industry, and digital growth priority areas. The funds will be put towards establishing digital capability centres to serve as hubs for AI research and development. These hubs will offer resources, training, and assistance to SMEs, enabling them to create and deploy AI technologies. Consequently, the surge in governmental support is expected to fuel the expansion of the AI in pharma market in the forecasted period.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3887&type=smp

What Long-Term Trends Will Define the Future of the AI In Pharma Market?
A primary trend in the AI for pharma market is the introduction of new AI tools by sector businesses, benefiting pharma companies. AI aids in areas such as quality assurance, anticipatory maintenance, waste reduction, design improvement, and process automation. For example, Sanford Health and Sharp HealthCare, both US-based non-profit healthcare enterprises, collaborated with Dandelion Health, a healthcare AI company, in August 2022. They unveiled a substantial data platform offering healthcare institutions reliable access to representative patient data for clinical AI enhancement. The Dandelion Platform offers health AI developers an ethical, secure approach to patient datasets, including images, waveforms, and organized health records, to create tools and products beneficial to patients and healthcare providers.

Which Segments in the AI In Pharma Market Offer the Most Profit Potential?
The ai in pharmamarket covered in this report is segmented -

1) By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning
2) By Drug Type: Small Molecule, Large Molecules
3) By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction

Subsegments:
1) By Context-Aware Processing: Real-Time Data Processing, Contextual Recommendation Systems, Adaptive Learning Systems
2) By Natural Language Processing (NLP): Text Analytics And Sentiment Analysis, Chatbots And Virtual Assistants, Document And Data Mining
3) By Querying Method: Structured Querying, Unstructured Querying, Semantic Search Technologies
4) By Deep Learning: Neural Networks For Drug Discovery, Image Recognition For Medical Imaging, Predictive Analytics Models

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3887&type=smp

Which Firms Dominate the AI In Pharma Market by Market Share and Revenue in 2025?
Major companies operating in the AI in pharma market include Concerto HealthAI, Alphabet Inc., OWKIN, Nvidia Corporation, PathAI, Insilico Medicine, Exscientia, Microsoft Corporation, XtalPi, Intel, Standigm, Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Jiangsu Hengrui Medicine Co. Ltd, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharma, Alliance Pharm Pte Ltd., Shanghai Pharmaceuticals, DeepMind, GlaxoSmithKline, Sanofi, Bayer, Renalytix AI, Merck, AstraZeneca, Iktos, Benevolent AI, Novartis, Ardigen, Botkin, Webiomed, Care Mentor AI, Diagnocat, IBM Corporation, Atomwise Inc., Cloud Pharmaceuticals, Bioage, NuMedii, Envisagenics, Aria Pharmaceuticals, Verge Genomics, Berg LLC, Cyclica, IQVIA, Roche, Pfizer, PRA Health Science, Gesto, Intensicare, Epitrack, Deep Genomics Inc., Welltok Inc., Oncora Medical, Recursion Pharmaceuticals Inc., Nucleai, Pepticom, Rology, hearX Group, DilenyTech, iNNOHEALTH Technology Solutions

Which Regions Offer the Highest Growth Potential in the AI In Pharma Market?
North America was the largest region in the AI in pharma market in 2024. The regions covered in the AI in pharma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3887

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.